The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Predictive And Presymptomatic Testing Market Be By 2030 Compared To Its 2026 Market Size?
The predictive and presymptomatic testing market has experienced substantial expansion recently. This market is projected to expand from $5.78 billion in 2025 to reach $6.37 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this growth has been driven by several factors, including developments in genetic sequencing technologies, greater public understanding of inherited disease risks, an increase in clinical genetic testing offerings, the rise of oncology and neurology testing initiatives, and the reduction in genetic testing expenses.
The predictive and presymptomatic testing market is anticipated to experience robust expansion over the coming years. This market is projected to reach $9.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.0%. Several factors will drive this growth during the forecast period, including an escalating demand for personalized medicine, enhanced integration of AI into genomic analysis, the proliferation of population-scale screening initiatives, a heightened emphasis on preventive healthcare approaches, and increasing regulatory backing for genetic diagnostics. Key trends anticipated during this period encompass the wider embrace of preventive genetic screening, increased utilization of risk-based models for disease prediction, an expansion of genetic counseling services, a sharpened focus on detecting diseases early, and the incorporation of genomic data into clinical decision-making processes.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20594&type=smp
Which Major Drivers Are Influencing The Expansion Of The Predictive And Presymptomatic Testing Market?
The expanding occurrence of genetic conditions is anticipated to fuel the future expansion of the predictive and presymptomatic testing market. These disorders stem from abnormalities in deoxyribonucleic acid (DNA), such as gene mutations and chromosomal alterations, exemplified by conditions like cystic fibrosis and Down syndrome. The growing frequency of genetic disorders can be linked to factors including higher maternal age, environmental influences, and improved diagnostic techniques. Predictive and presymptomatic testing is vital for diminishing the incidence of genetic disorders, as it pinpoints at-risk individuals prior to symptom onset. Such a proactive strategy enables early interventions or changes in lifestyle that can aid in preventing or lessening the seriousness of these conditions. As an illustration, in June 2023, the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, reported a 10% increase in gene therapies in Phase III clinical trials during quarter 3, 2023, marking the first quarterly rise since quarter 3, 2022. Consequently, the increased occurrence of genetic disorders is propelling the predictive and presymptomatic testing market.
How Are Different Segments Classified In The Predictive And Presymptomatic Testing Market Segment Analysis?
The predictive and presymptomatic testing market covered in this report is segmented –
1) By Test Type: Predictive Testing, Presymptomatic Testing
2) By Application: Cancer Genetic Testing, Cardiovascular Genetic Testing, Neurological Genetic Testing, Other Applications
3) By End User: Hospitals And Clinics, Diagnostic Laboratories
Subsegments:
1) By Predictive Testing: Genetic Testing for Inherited Conditions, Cancer Risk Prediction, Cardiovascular Disease Prediction, Neurodegenerative Disease Risk Prediction, Genetic Screening for Autosomal Dominant Disorders
2) By Presymptomatic Testing: Huntington’s Disease Testing, Hereditary Cancer Risk Testing, Cystic Fibrosis Presymptomatic Testing, Early-Onset Alzheimer’s Disease Testing, Presymptomatic Genetic Testing for Familial Diseases
Which Trends Are Shaping The Predictive And Presymptomatic Testing Market?
Leading firms active within the predictive and presymptomatic testing market are concentrating on creating advanced multi-gene testing solutions that feature improved genetic risk-scoring, facilitating earlier identification of diseases and enhancing tailored prevention approaches. These polygenic panels integrate the sequencing of relevant hereditary-risk genes with the examination of numerous common genetic variations, offering a more thorough and personalized evaluation of an individual’s future disease susceptibility compared to conventional single-gene tests. An example of this is seen in November 2025, when Myriad Genetics Inc., a U.S.-based molecular diagnostics company, broadened its MyRisk Hereditary Cancer Test to encompass 63 clinically actionable genes spanning over 11 cancer types. This expanded panel incorporates next-generation sequencing technology with personalized lifetime and five-year cancer-risk estimates, empowering medical professionals to guide proactive decisions in patient care. The offering improves the detection of risk even for those without significant family histories, aiding in targeted monitoring, initiating screenings sooner, and planning preventive treatments.
Who Are The Companies Driving Activity In The Predictive And Presymptomatic Testing Market?
Major companies operating in the predictive and presymptomatic testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Mayo Clinic, Quest Diagnostics Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Peter MacCallum Cancer Centre, Myriad Genetics Inc., SomaLogic Inc., Siteman Cancer Center, Dante Labs S.R.L., Mapmygenome, Manipal Health Enterprises, Gene Vision, Reliance Diagnostic, GenepoweRx, Personal Genomics, Apollo Hospitals Enterprise Limited, Cardio Diagnostics Inc.
Get The Full Predictive And Presymptomatic Testing Market Report:
Which Region Is The Leading Market For The Predictive And Presymptomatic Testing Market?
North America was the largest region in the predictive and presymptomatic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive and presymptomatic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Predictive And Presymptomatic Testing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Predictive And Presymptomatic Testing Market 2026, By The Business Research Company
Central Precocious Puberty Market Report 2026
https://www.thebusinessresearchcompany.com/report/central-precocious-puberty-global-market-report
Premature Ejaculation Treatment Market Report
Hormone Therapy Market Report
https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model